Screener
Eli Lilly LLY Reportable Segment — Expenditures for long-lived assets
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Eli Lilly in its filing.
Tagged under the XBRL concept us-gaap:SegmentExpenditureAdditionToLongLivedAssets.
The source filing: Eli Lilly’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 2:40 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000059478-26-000081
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Early-stage research and development(1) | 1,450 | 1,156 | 2,715 | 2,146 |
| Late-stage research and development(1) | 2,368 | 2,180 | 4,613 | 3,924 |
| Marketing, selling, and administrative | 3,430 | 2,753 | 6,364 | 5,221 |
| Acquired in-process research and development | 2,776 | 154 | 3,360 | 1,726 |
| Other segment items(2) | 2,587 | 1,207 | 4,384 | 2,177 |
| Net income | $7,095 | $5,661 | $14,491 | $8,420 |
| Interest expense | $345 | $249 | $677 | $493 |
| Expenditures for long-lived assets(3) | 2,906 | 1,985 | 5,344 | 3,502 |
Item 1. Financial Statements
FAQ
- What is Eli Lilly's reportable segment — expenditures for long-lived assets?
- Eli Lilly (LLY) reported reportable segment — expenditures for long-lived assets of $2.91B in Q2 2026.
- How has Eli Lilly's reportable segment — expenditures for long-lived assets changed year-over-year?
- Eli Lilly's reportable segment — expenditures for long-lived assets increased by 46.4% year-over-year, from $1.99B to $2.91B.
- What is the long-term trend for Eli Lilly's reportable segment — expenditures for long-lived assets?
- Over 3 years (2022 to 2025), Eli Lilly's reportable segment — expenditures for long-lived assets has grown at a 55.9% compound annual growth rate (CAGR), from $2.29B to $8.67B.
- What does reportable segment — expenditures for long-lived assets mean?
- Measures the capital invested by the segment into tangible or intangible assets expected to provide benefits over multiple years. This includes investments in manufacturing facilities, laboratory equipment, and infrastructure necessary to support production capacity. It reflects the segment's commitment to long-term operational scaling and capacity expansion.
Ask your AI about Eli Lilly's reportable segment — expenditures for long-lived assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude